Interaction between clopidogrel and PPI can lead to increased mortality

Emerging evidence indicates that proton-pump inhibitors (PPI) may inhibit cytochrome P450 2C19, an enzyme that plays a critical role in influencing the anti-platelet effect of clopidogrel.¬† This paper sought to characterize whether the use of clopidogrel and PPI concomitantly was associated with adverse outcomes following hospital discharge for myocardial infarction (MI). […]

Read More…

Genetic polymorphisms and response to clopidogrel and risk of cardiovascular events

Across the whole spectrum of acute coronary syndromes and in patients undergoing PCI and stenting, dual anti-platelet therapy with aspirin and clopidogrel is the current recognised standard of care. However, significant variation in response to clopidogrel is observed between patients, with those with lesser degrees of platelet inhibition being at higher risk of adverse cardiovascular […]

Read More…